PROF: Profound Medical Company Sales Revenue

Exclusive patents for TULSA-PRO and stringent FDA oversight create a powerful defensive moat for Profound Medical Corp. (PROF). The company's gross sales volume demonstrates business resilience, with the current figure standing at 0.02. Revenue is driven by the supply of systems and consumables to clinics. The scaling of prostate cancer therapy is accelerating revenue growth while the market awaits the expansion of insurance coverage.

Revenue and Sales Volume: Profound Medical Corp (PROF) for 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Profound Medical Corp (PROF)

- stock value and consensus price forecast:

Stock Quotes Profound Medical Corporation|PROF - Consensus Target

- market capitalization information:

Market Value Profound Medical Corp.|PROF - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share Profound Medical|PROF - Book Capitalization|Market-to-Book Ratio profoundmedical.com|PROF - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

PROF - Net Income|Expected Net Income Profound Medical Corp.|PROF - P/E Multiple|Projected Price to Earnings Ratio Profound Medical Corporation|PROF - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple Profound Medical Corp.|PROF - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Profound Medical|PROF - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months profoundmedical.com|PROF - Earnings per share growth in current year|Net earnings per share change forecast for next year Profound Medical Corp.

- company sales and revenue statistics:

PROF - Company Revenue|Company Future Sales Volume Profound Medical Corporation|PROF - P/S Multiple|Market Cap to Future Revenue Ratio Profound Medical Corp.

Summary company analysis:PROF profoundmedical.com

Investors are assessing the potential of Profound Medical Corp. (PROF) through the lens of the commercialization of its innovations. This indicator tracks daily revenue, reflecting resource management efficiency and the risk of cash flow gaps. By analyzing the company's sales metrics, one can evaluate the adoption rate of ablation systems in urological clinics. This price action confirms the synergy of strategic alliances and real demand for the equipment. The asset belongs to the high-tech medical sector.

Key competitors